Bandrone 50 — Ibandronic Acid 50 mg Tablets, 10 Tablets

Bandrone 50 is supplied as film-coated tablets containing 50 mg of ibandronic acid.

Qualitative and Quantitative Composition per Tablet:

• Active Ingredient: Sodium ibandronate monohydrate (equivalent to ibandronic acid) — 50 mg.
• Excipients: Lactose monohydrate, povidone, crospovidone, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, hypromellose, macrogol, titanium dioxide.

Packaging and Presentation: White to off-white, round, biconvex film-coated tablets with debossing. 10 tablets per carton along with official prescribing information. The outer box and blisters display Bandrone 50 (Ibandronic Acid Tablets I.P.) and Natco Pharma corporate graphics.

Pharmacodynamics:
Ibandronic acid is a potent nitrogen-containing bisphosphonate. It acts selectively on bone tissue by binding to active mineralization sites. The drug inhibits osteoclast activity, leading to reduced bone destruction, lower fracture frequency, decreased hypercalcemia, and reduced need for analgesic therapy.

Pharmacokinetics:

• Absorption: Rapidly absorbed from the gastrointestinal tract, though absolute bioavailability is low (< 0.6%). Food and beverages (other than plain water) significantly impair absorption.
• Distribution: Following absorption, rapidly binds to bone tissue or is excreted renally. Plasma protein binding is approximately 85–87%.
• Metabolism: Not metabolized in the human liver or body.
• Elimination: Absorbed fraction is eliminated exclusively via the kidneys unchanged. Unabsorbed fraction is eliminated fecally. Terminal half-life ranges from 10 to 72 hours.

Bandrone 50 is indicated in adult patients for:

• Bone Metastases in Breast Cancer: Prevention of skeletal-related events (pathological fractures, bone pain requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
• Malignancy-Associated Hypercalcemia: Management of tumor-induced hypercalcemia (primarily utilized in supportive settings per oncologist guidance).

Bandrone 50 is administered orally once daily at a dose of 50 mg.

Administration Instructions (Strict Requirements to Ensure Absorption):

• Take in the morning on an empty stomach after overnight fasting (at least 6 hours prior to food or drink).
• Swallow tablet whole with a full glass of plain drinking water (200–250 ml). Do not use mineral water, juice, tea, or coffee.
• Patients must not lie down for at least 1 hour (60 minutes) following administration to prevent esophageal irritation.
• Avoid food, beverages (other than water), and other medications for at least 1 hour post-dose.

Administration of Bandrone 50 is contraindicated in:

• Hypersensitivity: Known hypersensitivity to ibandronic acid or any excipient.
• Esophageal Abnormalities: Esophageal abnormalities delaying emptying (e.g., stricture or achalasia).
• Inability to Stand/Sit Upright: Inability to stand or sit upright for at least 60 minutes.
• Hypocalcemia: Pre-existing uncorrected hypocalcemia.
• Severe Renal Impairment: Creatinine clearance < 30 ml/min.
• Pregnancy and Lactation: Contraindicated in pregnant or breastfeeding women.

Evaluated drug interactions for Bandrone include:

• Food, Calcium Supplements, and Antacids: Products containing calcium, magnesium, aluminum, or iron significantly impair ibandronic acid absorption. Administer at least 1 hour apart from Bandrone 50.
• NSAIDs (Aspirin, Ibuprofen): Because both bisphosphonates and NSAIDs may cause gastrointestinal irritation, caution is advised during co-administration.

Pregnancy:
Bandrone 50 is contraindicated during pregnancy. Human data are lacking; animal studies have shown reproductive toxicity.

Lactation:
It is unknown whether ibandronic acid passes into human breast milk. Contraindicated during lactation.

Adverse reactions associated with ibandronic acid are generally mild to moderate:

• Gastrointestinal Tract: Dyspepsia, nausea, abdominal pain, gastritis, esophagitis, heartburn, dysphagia.
• Musculoskeletal System: Arthralgia, myalgia, limb pain, jaw osteonecrosis (associated with long-term use and dental procedures).
• Nervous System: Headache, dizziness, asthenia.
• Laboratory Changes: Transient hypocalcemia, hypophosphatemia.
• Other: Hypersensitivity reactions, skin rash.

Symptoms:
Specific acute overdose data are limited. Potential manifestations include gastrointestinal upset (heartburn, esophagitis, nausea) and hypocalcemia (reduced serum calcium).

Treatment:
No specific antidote exists. Administration of milk or antacids to bind the drug in the GI tract, symptomatic care, and intravenous calcium administration if necessary.

Storage Requirements for Bandrone 50:

• 🌡️ Temperature Range: Store in a dry, light-protected place at temperatures not exceeding 25–30 °C.
• 💧 Moisture Protection: Keep in original packaging to protect tablets from moisture.
• 👶 Safety Precautions: Keep strictly out of reach of children.
• ⏳ Shelf Life: Stated on carton and blisters. Do not use past expiration date. Prescription-only medicine.

To verify the authenticity of genuine Bandrone 50 manufactured by Natco Pharma, inspect the following features:

• ✅ Corporate Logo: Distinctive blue-green Natco Pharma corporate logo printed on the outer carton and blister foil.
• ✅ Packaging Markings: Clear factory printing displaying Batch No., Mfg. Date, Exp. Date, and product designation Bandrone 50 (Ibandronic Acid Tablets I.P.).
• ✅ Box Quantity: Standard box contains exactly 10 tablets.
• ✅ Print Quality: High-grade packaging artwork without color fading or typography errors.